Dermatologic Therapy最新文献

Autoimmune bullous diseases (AIBDs) are a group of chronic disorders characterized by blister formation resulting from abnormal immune responses. Janus kinase (JAK) inhibitors have emerged as promising therapeutic agents for AIBDs. This review discusses the use of JAK inhibitors—such as upadacitinib, baricitinib, tofacitinib, and abrocitinib, among others—in the management of various AIBDs. We examine clinical evidence supporting their efficacy in conditions including bullous pemphigoid, pemphigus foliaceus, mucous membrane pemphigoid, paraneoplastic pemphigus, and other blistering diseases. Additionally, the review covers histological findings related to JAK inhibition, the role of the JAK/STAT signaling pathway in AIBD pathogenesis and treatment, and the therapeutic benefits of different JAK inhibitors. Finally, we highlight the potential of these agents to improve clinical outcomes, while also acknowledging the limitations of existing research.

Histone methyltransferase nuclear receptor binding SET domain protein 3 (NSD3) has been reported to promote cell proliferation in a variety of cancer cells. However, whether NSD3 regulates cell proliferation in psoriatic cells is unknown. Here, we found elevated expression of NSD3S (the short isoform with no activity) but not NSD3L (the long isoform) in psoriatic keratinocytes, and specific knockdown of NSD3S expression decreases cell proliferation of psoriatic keratinocytes. Further investigation has shown that NSD3S knockdown destabilizes c-Myc protein but does not suppress the transcription of the c-MYC gene. Notably, a cell-penetrating peptide TAT-tagged inhibitory peptide TAT–NSD3^389–404 targeting NSD3–c-Myc interaction destabilizes c-Myc protein in a similar way, suggesting that NSD3S stabilizes c-Myc through interaction. Most importantly, treatment with TAT–NSD3^389–404 peptide alleviates psoriatic symptoms and decreases the Psoriasis Area and Severity Index (PASI) score, the lesion thickness, and the concentration of psoriasis-related cytokines (IL-17, IL-6, and CXCL1) in imiquimod-induced psoriasis-like mice, suggesting NSD3–c-Myc interaction may be a potential therapeutic target for psoriasis.

Hyperthermia represents a physiological state marked by an elevation in body temperature due to the malfunctioning of thermoregulatory mechanisms. It transpires when the body either generates or absorbs a greater amount of heat than it is capable of expelling. In clinical practice, hyperthermia has gained increasing recognition compared with traditional laser, freezing, and other treatment measures. However, the regulatory effects of hyperthermia on immune cells and the underlying mechanisms remain insufficiently investigated. In this review, we summarized the therapeutic methods of hyperthermia including thermal water hyperthermia, infrared radiation (IR) hyperthermia, photodynamic therapy, and targeted radiofrequency hyperthermia in dermatology, the clinical practical applications as well as the treatment mechanism based on immune cells. Further studies should be conducted to clarify the underlying mechanisms and promote the clinical applications of hyperthermia.

Chronic plaque psoriasis negatively impacts patients’ work productivity, with potential substantial financial implications. This post hoc analysis assessed associations between disease (itch, pain, dermatology life quality index [DLQI], and psoriasis area and severity index [PASI])- and work-related outcome measures (absenteeism, presenteeism, and activity and work impairment) in 116 patients with moderate-to-severe plaque psoriasis treated with tildrakizumab for 24 weeks. We extrapolated the potential economic value of reducing work productivity loss with tildrakizumab treatment in society, using Norway as a model. Elevated pain and DLQI scores significantly increased the degree of absenteeism, and pain, DLQI, and itch were significantly positively associated with presenteeism, activity impairment, and work impairment. The PASI did not associate with any work outcome measure. Economic impact due to work productivity loss was extrapolated at approximately EUR 12,700 per person annually. In conclusion, all disease outcome measures except the PASI were associated with a work-related outcome measure, indicating that more holistic measures for assessing psoriasis disease burden may be more beneficial from a patient perspective. Additionally, the economic value of reduced work productivity loss due to tildrakizumab treatment was extrapolated to be substantial in Norwegian society, suggesting that managing plaque psoriasis with this biologic could be clinically and economically beneficial.